EDAP TMS SA and Avenda Health have partnered to enhance prostate cancer care by integrating advanced AI technology with robotic ultrasound procedures, aiming for more precise and less invasive treatments.
EDAP TMS SA and Avenda Health are collaborating to enhance prostate cancer care through an innovative integration of technology. Last month, the two companies announced their partnership to utilise Avenda Health’s Unfold AI technology alongside EDAP’s Focal One robot, introducing a new approach to high-intensity focused ultrasound (HIFU) procedures.
Avenda Health’s Unfold AI system, which has received clearance from the U.S. Food and Drug Administration (FDA), offers a multimodal AI decision-support platform. This platform is capable of constructing detailed 3D cancer maps that reveal the precise extent and location of prostate tumours, which might not be fully visible using traditional imaging methods. By providing such detailed insight, the technology aims to enhance the accuracy of HIFU procedures, enabling clinicians to effectively target cancerous tissues while preserving as much surrounding healthy tissue as possible.
The integration combines Avenda’s AI planning capabilities with the targeted precision of the Focal One robotic HIFU platform. According to the companies, this synergy allows urologists to deliver more personalised and precise treatments to prostate cancer patients, offering a more focused and less invasive alternative to traditional prostate cancer therapies.
Dr. Wayne G. Brisbane, an assistant professor of urology at the University of California, Los Angeles David Geffen School of Medicine, has been involved in the development and implementation of this novel treatment system. As Dr. Brisbane explained, the Focal One system empowers surgeons to ablate specific areas of the prostate rather than treating the entire prostate, which is a significant advance towards reducing the side-effects often associated with prostate cancer treatment. He emphasised that the integration of the 3D mapping technology from Unfold AI allows for a better prediction of tumour extent and a robotic-guided treatment approach, potentially minimising the risks of incomplete tumour ablation and cancer recurrence.
The application of Focal One involves fusing data from multiple sources, including MRI scans, PSA levels, biopsy locations, and Gleason scores, to create a comprehensive and accurate map. This guidance is crucial for performing precise ablations and thus improving patient outcomes. Despite the usual risks associated with HIFU, such as changes in urinary and sexual functions and concerns about cancer recurrence due to incomplete treatment, the technological integration aims to mitigate these challenges by enhancing precision and targeting.
In terms of workflow, Dr. Brisbane noted that Focal One offers a user-friendly interface that seamlessly integrates with Unfold AI, making it easier for medical professionals to adopt within existing clinical practice frameworks.
Patient response to this pioneering technology has been overwhelmingly positive. The targeted approach and reduced invasiveness compared to traditional methods have been particularly well-received, with patients reporting fewer side effects and a greater sense of relief and confidence in their treatment outcomes. The detailed insights provided by the 3D cancer maps have been instrumental in helping physicians select patients for focal therapy, particularly those who might not qualify for more traditional treatments.
Reflecting on the future, Dr. Brisbane is optimistic about the broader applications of Unfold AI’s capabilities. He anticipates that similar AI mapping technologies may be adapted to other robotic platforms and surgical procedures, potentially revolutionising a wide array of medical practices beyond urology. This partnership between EDAP TMS SA and Avenda Health thus not only hints at immediate benefits for prostate cancer care but also opens the door to a transformative era in precision medicine.
Source: Noah Wire Services
